HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Britta Weigelt Selected Research

Immunotherapy

11/2023Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
11/2023Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications.
1/2022Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
1/2022Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
1/2021PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Britta Weigelt Research Topics

Disease

125Neoplasms (Cancer)
05/2024 - 06/2002
55Breast Neoplasms (Breast Cancer)
05/2024 - 08/2004
20Carcinoma (Carcinomatosis)
11/2023 - 08/2004
18Endometrial Neoplasms (Endometrial Cancer)
03/2024 - 05/2011
11Ovarian Neoplasms (Ovarian Cancer)
04/2024 - 11/2017
6Adenocarcinoma
01/2024 - 05/2011
6Neoplasm Metastasis (Metastasis)
12/2022 - 01/2014
5Microsatellite Instability
02/2024 - 12/2018
5Lobular Carcinoma
02/2024 - 07/2013
5Triple Negative Breast Neoplasms
01/2021 - 01/2011
5Papillary Carcinoma
01/2020 - 02/2012
4Sarcoma (Soft Tissue Sarcoma)
12/2022 - 01/2016
4Ductal Carcinoma
12/2014 - 11/2009
3Disease Progression
01/2023 - 05/2011
3Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer)
01/2022 - 01/2020
3Mucinous Adenocarcinoma (Mucinous Carcinoma)
01/2021 - 01/2019
3Acinar Cell Carcinoma
12/2019 - 10/2015
3Endometrioid Carcinoma
09/2017 - 04/2015
2Uterine Cervical Neoplasms (Cancer of the Cervix)
11/2023 - 08/2021
2Small Cell Carcinoma
10/2022 - 10/2021
2Fibroadenoma
02/2022 - 11/2015
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 01/2016
2Carcinogenesis
01/2022 - 01/2020
2Residual Neoplasm
01/2022 - 08/2015
2Lung Neoplasms (Lung Cancer)
01/2022 - 01/2021
2Noninfiltrating Intraductal Carcinoma (DCIS)
01/2021 - 05/2014
2Adenomyoepithelioma
01/2021 - 01/2018
2Adenoid Cystic Carcinoma (Cylindroma)
01/2021 - 03/2010
2DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes)
01/2020 - 01/2017
2Brain Neoplasms (Brain Tumor)
04/2018 - 05/2011
2Fibrocystic Breast Disease (Chronic Cystic Mastitis)
01/2017 - 04/2016
2Metaplasia
01/2017 - 03/2015
2Lymphatic Metastasis
01/2014 - 02/2012
1Ovarian Diseases (Ovarian Disease)
03/2024
1Endometrial Hyperplasia
11/2023

Drug/Important Bio-Agent (IBA)

26DNA (Deoxyribonucleic Acid)IBA
01/2023 - 08/2004
24Estrogen ReceptorsIBA
01/2023 - 08/2006
16RNA (Ribonucleic Acid)IBA
11/2023 - 12/2014
14Proteins (Proteins, Gene)FDA Link
11/2023 - 02/2013
13Phenobarbital (Luminal)FDA Link
02/2017 - 08/2006
10Hormones (Hormone)IBA
05/2024 - 07/2009
10Biomarkers (Surrogate Marker)IBA
05/2024 - 04/2011
8Trastuzumab (Herceptin)FDA Link
11/2023 - 07/2010
8Progesterone Receptors (Progesterone Receptor)IBA
01/2020 - 01/2007
6Cadherins (E-Cadherin)IBA
02/2024 - 11/2010
6Lapatinib (GW572016)FDA Link
01/2023 - 07/2010
6Formaldehyde (Formol)FDA Link
10/2019 - 01/2016
6ParaffinIBA
10/2019 - 01/2016
5Immune Checkpoint InhibitorsIBA
02/2024 - 01/2020
5MucinsIBA
01/2023 - 01/2019
4Circulating Tumor DNAIBA
01/2023 - 10/2013
4Cell-Free Nucleic AcidsIBA
01/2023 - 11/2017
4AntibodiesIBA
01/2020 - 11/2010
3CateninsIBA
11/2023 - 07/2013
3Telomerase (Telomerase Reverse Transcriptase)IBA
10/2023 - 02/2022
3Monoclonal AntibodiesIBA
10/2023 - 01/2019
3Mitogen-Activated Protein KinasesIBA
01/2022 - 10/2018
3Transcription Factors (Transcription Factor)IBA
01/2022 - 02/2017
3B7-H1 AntigenIBA
01/2022 - 01/2021
3Exonucleases (3' 5' Exonuclease)IBA
01/2020 - 04/2015
3Poly(ADP-ribose) Polymerase InhibitorsIBA
11/2017 - 05/2011
3Phosphatidylinositols (Phosphatidylinositol)IBA
05/2014 - 01/2012
3Messenger RNA (mRNA)IBA
06/2010 - 06/2002
3OligonucleotidesIBA
01/2010 - 01/2007
2Calbindin 2IBA
11/2023 - 01/2021
2pembrolizumabIBA
10/2023 - 08/2021
2Keratin-7 (Cytokeratin 7)IBA
01/2023 - 01/2021
2SynaptophysinIBA
01/2023 - 02/2017
2PlatinumIBA
11/2022 - 11/2017
2Mediator ComplexIBA
02/2022 - 11/2015
2MART-1 AntigenIBA
01/2022 - 01/2021
2Adenosine Triphosphatases (ATPase)IBA
01/2022 - 10/2021
2human ERBB2 proteinIBA
01/2020 - 01/2017
2Hematoxylin (Haematoxylon)IBA
01/2020 - 04/2015
2Eosine Yellowish-(YS) (Eosin)IBA
01/2020 - 04/2015
2Cyclin D1IBA
01/2020 - 11/2010
2Codon (Codons)IBA
01/2018 - 01/2018
2ClaudinsIBA
01/2017 - 03/2015
2Phosphotransferases (Kinase)IBA
06/2016 - 03/2012
2Proteasome Endopeptidase Complex (Proteasome)IBA
01/2016 - 08/2012
1Estrogen Receptor Modulators (Antiestrogen)IBA
05/2024
1APOBEC-1 DeaminaseIBA
05/2024
1Peptides (Polypeptides)IBA
05/2024
1EnzymesIBA
05/2024
1NivolumabIBA
04/2024
1ProgesteroneFDA LinkGeneric
11/2023
1MB 3 (MB-3)IBA
11/2023
1Estrogen Receptor alphaIBA
11/2023
1Immunoconjugates (Immunoconjugate)IBA
11/2023
1Ado-Trastuzumab EmtansineIBA
11/2023
1lenvatinibIBA
10/2023
1Tyrosine Kinase InhibitorsIBA
10/2023
1Death Domain ReceptorsIBA
10/2023

Therapy/Procedure

48Therapeutics
05/2024 - 06/2010
12Drug Therapy (Chemotherapy)
01/2023 - 09/2009
5Immunotherapy
11/2023 - 01/2021
5Neoadjuvant Therapy
01/2023 - 08/2015
5Radiotherapy
10/2022 - 05/2011
3Precision Medicine
10/2017 - 01/2014
1Ovariectomy (Oophorectomy)
03/2024